TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04588181

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral therapy (CBT)
Description: Cognitive behavioral therapy (CBT) is a psycho-social intervention that aims to improve mental health. CBT focuses on challenging and changing unhelpful cognitive distortions (e.g. thoughts, beliefs, and attitudes) and behaviors, improving emotional regulation, and the development of personal coping strategies that target solving current problems.
Study: NCT01600092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RotaTeq™ experimental formulation
Study: NCT04615611

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of placebo
Study: NCT00151320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib, CHOP, Rituximab
Description: Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)~VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:~Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4
Study: NCT02490722

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: Four times two hours group based patient education
Study: NCT01555268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trebananib
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trebananib
Description: Given IV
Study: NCT02051712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: individualized exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence measures
Description: Measures to increase adherence to exercise training
Study: NCT03022916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nail Polish + Efinaconazole Solution
Description: Application of Jublia to the nail of one big toe on top of the nail polish

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nail polish
Description: Application of nail polish only to both big toe nails

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Base Coat + Nail Polish + Top Coat + Efinaconazole Solution
Description: Application of Jublia to the nail of one big toe on top of the nail polish with layers of top coat and base coat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nail Polish + Top Coat + Efinaconazole Solution
Description: Application of Jublia to the nail of one big toe on top of the nail polish with layer of top coat
Study: NCT02368314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Enoxaparine
Description: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Enoxaparine
Description: 30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
Study: NCT01562938

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-557
Description: MEDI-557 low-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-557
Description: MEDI-557 high-dose
Study: NCT03631316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Valganciclovir
Description: 900 mg daily during 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Innovative Valganciclovir
Description: 900 mg daily during 4 days
Study: NCT03482973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Group
Description: 20cc bupivacaine hydrochloride will be administered on each side at two different time points (immediately post operatively and on day 1).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20cc placebo (0.9% NaCl) will be administered on each side at two different time points (immediately post operatively and on day 1).
Study: NCT01720225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
Study: NCT03605082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB0107
Description: * Pharmaceutical form: solution for infusion~* Route of administration: intravenous use

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Pharmaceutical form: solution for infusion~* Route of administration: intravenous use
Study: NCT00788541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 6 mg/mL
Description: Administered as an injection into an anterior juxtascleral depot
Study: NCT04031625

Intervention type: OTHER
Intervention: Metastatic Colorectal Cancer Database
Description: Metastatic Colorectal Cancer Database
Study: NCT02671747

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Over Matter; Healthy Bowels, Healthy Bladder
Description: 3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
Study: NCT02685735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
Study: NCT00788541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 3.75 mg/mL
Description: Administered as an injection into an anterior juxtascleral depot
Study: NCT02685735

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
Study: NCT00986050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abciximab
Description: Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bare metal stent prokinetic, chrono, skylor or bluemedical
Description: bare metal stent in culprit artery in acute myocardial infarction

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: drug eluting stent (sirolimus eluting) - CYPHER stent
Description: stent implantation in culprit artery in acute myocardial infarction
Study: NCT00788541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate Sterile Suspension, 96 mg/mL
Description: Administered as an injection into an anterior juxtascleral depot
Study: NCT01555268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC
Study: NCT01795417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF XP200
Description: Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XP200 RF device
Description: 4 RF treatments of periorbital region on one side of the face
Study: NCT01555268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00378144

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine/Paracetamol
Description: Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime \[Paracetamol (500 mg) and Pseudoephedrine (30 mg)\]
Study: NCT03226535

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-CT Fusion
Description: The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
Study: NCT02309307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tissue Repair Device (VergenixTM STR)
Description: Administration of Soft Tissue Repair Device
Study: NCT03220854

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: humanized anti-PD-1 monoclonal antibody
Description: Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: humanized anti-PD-1 monoclonal antibody
Description: Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
Study: NCT01555268

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT01653496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery
Description: The main 18 elements of ERAS program included are described in detail in the brief summary of the study
Study: NCT03836963

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive training
Description: Cognitive training consists of a set of computerize games played on an iPad at home. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: active control cognitive training
Description: The active control consists of a set of computerized games played on an iPad. Training will include 4 sessions/week for 8 weeks. Each session will take 30min. Total hours of training is 16 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory strategy training
Description: the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: memory strategy training
Description: the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: memory strategy training
Description: the participant's prospective memory strategies will be developed with researchers. Participants will be engage in the strategies daily; this will take only a few minutes a day to accomplish.
Study: NCT02067910

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept SC
Description: Weekly subcutaneous administration of 125 mg Abatacept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept SC
Description: Weekly subcutaneous administration of 125 mg Abatacept
Study: NCT03608514

Intervention type: DRUG
Group type: OTHER
Intervention: Experimental
Description: Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental
Description: Patients in this arm of the study will receive intravenous infusion (IVi) terlipressin by rate 1-2µg/kg/min.
Study: NCT03375021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX717 200 mg
Description: CX717 200 mg capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX717 200 mg
Description: CX717 200 mg capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX717 800 mg
Description: CX717 4 X 200 mg capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX717 800 mg
Description: CX717 4 X 200 mg capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 200 mg or 800 mg capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 200 mg or 800 mg capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 200 mg or 800 mg capsules BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo 200 mg or 800 mg capsules BID
Study: NCT01242956

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: verum group
Description: video-based training after stroke

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: non-video group
Study: NCT00857220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: One 2 mg tablet per day for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eszopiclone
Description: one 3mg tablet per day for 12 months
Study: NCT01600092

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RotaTeq™ existing formulation
Study: NCT05380167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BRJ Nitrate
Description: Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink with nitrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: BRJ Placebo
Description: Participants in this group drank daily for 12 weeks a 70 mL bottle of Beet It Sport drink without nitrate
Study: NCT02982083

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raloxifene hydrochloride
Description: 20 patients consume raloxifene hydrochloride oral tablet daily for one year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: 20 patients consume placebo oral tablets daily for one year.
Study: NCT01410188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-6566
Description: OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-6566
Description: OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-6566
Description: OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-6566
Description: OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost
Description: Latanoprost (one drop once per day for 4 weeks)
Study: NCT01900288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPN Group Clinic Appointments using Mobile Devices (experimental)
Description: Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mobile Device Access (placebo)
Description: Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
Study: NCT04911972

Intervention type: PROCEDURE
Intervention: Functional muscle transfer
Description: Muscle transfer to restore lower limb function
Study: NCT01170078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Hospira
Description: IV dose 3 times a week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epogen
Description: IV dose 3 times a week
Study: NCT00875862

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene catheter with Ropivicaine or normal saline
Description: Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Interscalene catheter with Ropivicaine or normal saline
Description: Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
Study: NCT02178267

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri (biogai AB, Sweden)
Description: Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
Study: NCT02678299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PREBEN
Study: NCT04684992

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GEBT Telehealth Administration Usability
Description: Establish the usability of a telehealth platform for the administration of GEBT
Study: NCT01137019

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-eluting stent
Description: The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus-eluting coronary stent
Description: The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
Study: NCT03459456

Intervention type: BEHAVIORAL
Intervention: Provocation OC task (Provoc)
Description: used to evoke OC-related distress

Intervention type: BEHAVIORAL
Intervention: Provocation OC task (Provoc)
Description: used to evoke OC-related distress

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test (TSST)
Description: used to evoke anxiety unrelated to OCD (e.g., performance anxiety)

Intervention type: BEHAVIORAL
Intervention: Trier Social Stress Test (TSST)
Description: used to evoke anxiety unrelated to OCD (e.g., performance anxiety)

Intervention type: BEHAVIORAL
Intervention: Exposure provocation task
Description: used to elicit overt OCD rituals

Intervention type: BEHAVIORAL
Intervention: Exposure provocation task
Description: used to elicit overt OCD rituals
Study: NCT03436823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse semi-structured interview
Description: The first session of rTMS is D1. From the first meeting to D14 semi -structured interviews are set up

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Music & Relaxation with eyes closed
Description: The first session of rTMS is D1. From the first meeting to D14 music \& relaxation with eyes closed sessions are set up
Study: NCT01848366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biowave Treatment
Description: Twelve weekly treatments
Study: NCT02461888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Chemotherapy
Study: NCT03220854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological: humanized anti-PD-1 monoclonal antibody
Description: Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
Study: NCT02461888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Chemotherapy
Study: NCT03678233

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AndroGel 16.2 mg/L
Description: Testosterone gel 1.62 % will be applied to upper arms or shoulders once a day at 9:00 am to dry and intact skin for a period of 28 days or until ICU discharge. The daily dose 101.25 mg in men and 20.25 mg in women.
Study: NCT01010152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Codeine Sulfate
Description: 30 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine Sulfate
Description: 30 mg Tablet
Study: NCT06071156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anakinra
Description: Anakinra, an IL-1 antagonist, is particularly interesting because it limits the self-sustained pathway of recurrent pericarditis and may reduce the recurrences
Study: NCT00303888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idronoxil
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: Given orally